Physician profile
Laura Markwick
NPI 1740363886
$10,326.80
in general payments reported to CMS, 2019-2025
29 companies · $2,358 in 2025
The $2,358 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,274 · 2022: $2,010 · 2023: $1,712 · 2024: $1,973 · 2025: $2,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,042.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,974.42 | 2021-2025 | |
| Novo Nordisk INC | $1,346.22 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,102.57 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Pfizer INC. | $940.14 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $516.63 | 2024-2025 | Strensiq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $434.05 | 2021-2025 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $382.04 | 2021 | |
| Axsome Therapeutics, INC. | $319.40 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $290.93 | 2022-2025 | Caplyta |
| Amgen INC. | $254.48 | 2021-2025 | Repatha |
| Exact Sciences Corporation | $254.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $227.10 | 2024-2025 | Voquezna |
| Braeburn INC. | $220.42 | 2024-2025 | Brixadi |
| Biohaven Pharmaceutical Holding Company LTD. | $185.98 | 2022 | |
| Lundbeck LLC | $159.47 | 2023-2025 | Vyepti, Rexulti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $149.13 | 2021-2025 | Zubsolv |
| Glaxosmithkline, LLC. | $127.09 | 2021-2023 | Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $106.31 | 2021-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.77 | 2022 | |
| Amneal Pharmaceuticals LLC | $49.44 | 2024 | Unithroid |
| Alkermes, INC. | $41.22 | 2021-2022 | |
| Indivior INC. | $39.75 | 2021-2023 | Sublocade |
| Vbi Vaccine (Delaware) INC. | $37.40 | 2023 | Prehevbrio |
| Sunovion Pharmaceuticals INC. | $24.96 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $23.70 | 2025 | |
| Paratek Pharmaceuticals, INC. | $18.67 | 2025 | Xhance, Nuzyra |
| Vanda Pharmaceuticals INC. | $15.50 | 2025 | Fanapt |
| Genentech USA, INC. | $14.73 | 2021 | |
| Neurocrine Biosciences, INC. | $12.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Markwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.